

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 4

**Complete If Known**

Application Number	10/802,342
Filing Date	03/17/2004
First Named Inventor	Peter Bedding
Art Unit	1615
Examiner Name	Isis A D Ghali
Attorney Docket Number	7593-CIP

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/I.G./	1	McClure SR, Glickman LT, Glickman NW. Prevalence of gastric ulcers in show horses. J Am Vet Med Assoc 1999;215: 1130-1 133.	
	2	Traub-Dargatz JL, Koprak CA, Seitzinger AH, Garber LP, Forde K, White NA. Estimate of the national incidence of and operation-level risk factors for colic among horses in the United States, spring 1998 to spring 1999. J Am Vet Med Assoc. 2001 Jul 1;219(1):67-71.	
	3	Lorenzo-Figueras M, Merritt AM. Effects of exercise on gastric volume and pH in the proximal portion of the stomach of horses. An J Vet Res. 2002;63:1481-1487	
	4	Mair, Tim, Tom Divers, and Norm Ducharme. Manual of Equine Gastroenterology. London: WB Saunders, 2002.	
	5	Mitchell RD. Prevalence of Gastric Ulcers in Hunter/Jumper and Dressage Horses Evaluated for Poor Performance. Assoc. Equine Sports Med., September 2001.	
	6	Kronfeld DS. Speed Limit. Dipl. ACVN, Dipl. ACVIM. March 2003 Article # 4212.	
	7	Pellegrini, Frank. A Large-scale Necroscopy of Equine Ulcers. Submitted to Equine Veterinary Journal, 2004.	
	8	Martin GP, Marriott C, Kellaway IW. The interaction of progesterone with mucus glycoproteins. Pharm Acta Helv. 1981;56(1):5-8.	
	9	Kiviluoto T, Paimela H, Mustonen H, Kivilaakso E. Exogenous surface-active Phospholipids protects Necturas gastric mucosa against luminal acid and barrier-breaking agents. Gastroenterology. 1991 Jan; 100(1):38-46.	
/I.G./	10	McNeil PL, Ito S. Gastrointestinal cell plasma membrane wounding and resealing in vivo. Gastroenterology. 1989 May; 96(5 Pt 1): 1238-48.	

Examiner  
Signature

/Isis Ghali/

Date  
Considered

02/02/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 1392016

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/802,342	
			Filing Date	03/17/2004	
			First Named Inventor	Peter Bedding	
			Art Unit	1615	
			Examiner Name	Isis A D Ghali	
Sheet	2	of	4	Attorney Docket Number	7593-CIP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/I.G./	11	Dupree JL, Coetzee T, Blight A, Suzuki K, Popko B (1998), Myelin galactolipids are essential for proper node of Ranvier formation in the CNS. J Neurosci 18(5):1642-49.	
	12	Kreitler B. Feed and Nutrition: Fat: The Next Nutraceutical? Thoroughbred Times, April 12,2003.	
	13	Davidson MH, Dugan LD, Bums JH, et al. The hypocholesterolemic effects of betaglucan in oatmeal and oat bran. A dose-controlled study. JAMA 1991;265:1833-9.	
	14	Bell S , Goldman VM, Bistrian BR, et al. Effect of beta-glucan from oats and yeast on serum lipids. Crit Rev Food Sci Nutr 1999;39:189-202 [review].	
	15	Braaten JT, Scott FW, Wood PJ, et al. High beta-glucan oat bran and oat gum reduce postprandial blood glucose and insulin in subjects with and without type 2 diabetes. Diabet Med 1994; 11:312-8.	
	16	Tappy LE, Gugolz E, et al. Effects of breakfast cereals containing various amounts of beta-glucan fibers on plasma glucose and insulin responses in NIDDM subjects. Diabetes Care 19(8):831-4.	
	17	Czop JK. The role of beta-glucan receptors on blood and tissue leukocytes in phagocytosis and metabolic activation. Pathol Immunopahtol Res 1985;5:286-96.	
	18	Estrada A, Yun CH, Van Kessel A, et al. Immunomodulatory activities of oat beta-glucan in vitro and in vivo. Microbiol Immunol 1997;41:99 1-8	
	19	Reid DM, Montoya M, et al. Expression of the beta-glucan receptor; Dectin-1, on murine leukocytes in situ correlates with its function in pathogen recognition and reveals potential roles in leukocyte interactions. J Leukoc Biol 76(1):86-94.	
	20	Bolm N, Kulicke W. Rlzeological studies of barley (1-3)(1-4) beta-glucan in Concentrated solution, Carbohydrate Research, 1999, 315, 293-301.	

Examiner Signature	/Isis Ghali/	Date Considered	02/02/2008
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/802,342		
		Filing Date	03/17/2004		
		First Named Inventor	Peter Bedding		
		Art Unit	1615		
		Examiner Name	Isis A D Ghali		
Sheet	3	of	4	Attorney Docket Number	7593-CIP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/I.G./	21	Wursch P, Sunyer FX. The role of viscous soluble fiber in the metabolic control of diabetes. A review with special emphasis on cereals rich in beta-glucan. Diabetes Care 20(11):1774-80.	
	22	Roth E, Spittler A, Oehler. Glutamine: effects on the immune system, protein balance and intestinal functions. Wien Klin Wochenshr. 1996;108(21):667-8.	
	23	Duckworth DH, Madison JB, et al. Arteriovenous differences for glutamine in the equine gastrointestinal tract. Am J Vet Res 53(10):1864-7.	
	24	Vazquez P, Gomez de Segura IA, Cos A, Candela CG, De Miguel E. Response of the intestinal mucosa to different enteral diets in situations of surgical stress and malnutrition. Nutr Hosp. 1996 Nov-Dec; 11(6):321-7	
	25	Bertolo RF, Chen CZ, Law G, Pencharz PB, Ball RO. Threonine requirement of neonatal piglets receiving total parenteral nutrition is considerably lower than that of piglets receiving an identical diet intragastrically. J Nutr. 1998 Oct; 128(10):1752-9.	
	26	Ball RO, Law G, Bertolo RFP, Pencharz PB. Adequate oral threonine is critical for mucin production and mucosal growth by neonatal piglet gut. Proceedings of the VIIIth International Symposium on Protein Metabolism and Nutrition, EAAP, 1999	
	27	Cuaron JA, Chapple RP, Easter RA. Effect of lysine and threonine supplementation of Sorghum in gestation diets on nitrogen balance and plasma constituents in first litter gilts. J. Anim. Sci., 58, 631-637	
	28	Bueno J, Torres A, Almendros A, Carmona R, Nunez MC and Gil A, (1994) Effect of dietary nucleotides on small intestinal repair after diarrhea. Histological and ultrastructural changes. Gut 35:926-933.	
	29	Uauy R, Stringel G, Thomas R and Quan R, (1990) Effect of dietary nucleosides on growth and maturation of the developing gut in the rat. J. Pediatr. Gastroenterol. Nutr. 10:497-503.	
	30	Marshman E., Booth C., Potten CS., The intestinal epithelial stem cell. Bioessays 2002 Jan; 24(1):91-8.	

Examiner Signature	/Isis Ghali/	Date Considered	02/02/2008
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/802,342	
			Filing Date	03/17/2004	
			First Named Inventor	Peter Bedding	
			Art Unit	1615	
			Examiner Name	Isis A D Ghali	
Sheet	4	of	4	Attorney Docket Number	7593-CIP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/I.G./	31	Lin, Cheng-mao. Effect of Dietary Nucleotide Supplementation on In Vivo and In Vitro Immune Function in Protein-Malnourished Mice. University of Florida. PhD. Dissertation. December 1995.	
/I.G./	32	Ip WK, Lau YL. Role of mannose-binding lectin in the innate defense against Candida albicans: enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. J Infect Dis 2004 Aug 1;190(3):632-40. Epub 2004 Jun 28.	
/I.G./	33	Swanson KS, Grieshop CM, Flickinger EA, Healy HP, Dawson KA, Merchen NR, Fahey GC Jr. Effects of supplemental fructooligosaccharides plus mannanoligosaccharides on immune function and ileal and fecal microbial populations in adult dogs. Arch Tierernahr. 2002 Aug;56(4):309-18.	
/I.G./	34	Bland EJ, Keshavarz T, Buclte C. The influence of small oligosaccharides on the immune system. Carbohydrate Research, vol 339, issue 10.	
/I.G./	35	Newman, K. 1994. Mannan-oligosaccharides: Natural polymers with significant impact on the gastrointestinal microflora and the immune system. Biotechnology in the Feed Industry, Nottingham University Press, Nottingham, UK, pp. 167-174.	
/I.G./	36	Davis E., Maxwell C., Kegley B., de Rodas B., Friesen K and Hellwig D., Efficacy of Mannan Oligosaccharide (Bio-Mos) Addition at Two Levels of Supplemental Copper on Performance and Immunocompetence of Early Weaned Pigs. Arkansas Animal Science Department Report 1999.	

Examiner Signature	/Isis Ghali/	Date Considered	02/02/2008
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/802,342
Filing Date	03/17/2004
First Named Inventor	Peter Bedding
Art Unit	1615
Examiner Name	Isis A D Ghali
Attorney Docket Number	7593-CIP

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
/I.G./		US-4,820,731	04-11-1989	Masdoli et al.	
		US- 4,950,858	08-21-1990	Lichtenberger	
		US- 5,320,848	08-14-1994	Bistrian et al.	
		US- 5,716,639	02-10-1998	Carlsson et al.	
		US- 5,972,985	10-28-1999	Thomas et al.	
		US- 6,020,324	02-01-2000	James et al.	
		US- 6,200,824	03-13-2001	Mazer et al.	
		US- 6,203,818	03-20-2001	Vester	
		US- 6,329,414	12-11-2001	Thomas et al.	
		US- 6,355,893	03-12-2002	Herskoff et al.	
		US- 6,759,064	07-06-2004	Morre et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
/I.G./		JP 09-262061	10-07-1997	Tanabe Seiyaku Co. Ltd.		

Examiner Signature

/Isis Ghali/

Date Considered

02/02/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/802,342
Filing Date	03/17/2004
First Named Inventor	Peter Bedding
Art Unit	1615
Examiner Name	Isis A D Ghali
Attorney Docket Number	7593-CIP

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/I.G./		WINAWER, NEIL M.D.; WILLIAMS, MARK V., M.D.; Making Health Care Safer: A Critical Analysis of Patient Safety Practices; Chapter 33, University of California at San Francisco (UCSF) - Stanford University Evidence-based Practice Center, AHRQ Publication 01-E058, July 20, 2001	

Examiner Signature	/Isis Ghali/	Date Considered	02/02/2008
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

MAY 24 2004

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

## Complete if Known

Application Number	10/802,342
Filing Date	March 17, 2004
First Named Inventor	Peter M. J. Bedding
Group Art Unit	
Examiner Name	
Attorney Docket Number	7593-CIP

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
/I.G./		US- 4,729,896	03/1988	Sawhill	
		US- 5,505,968	04/1996	Schaefer et al.	
		US-5,589,186	12/31/1996	Isobe et al.	
		US-5,660,852	08/1997	McKeown et al.	
		US- 5,759,537	06/02/1998	Garnett	
		US- 6,019,995	02/01/2000	Steensma	
		US- 6,045,834	04/04/2000	Howes et al.	
		US- 6,117,458	09/12/2000	Morgan	
		US- 6,344,221	02/05/2002	Evans	
		US- 6,410,067	06/2002	Kanter et al.	
		US- 6,451,370	09/17/2002	Anderson	
		US- 6,537,544	03/25/2003	Loenner	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

## FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
/I.G./		WO99/18188	04/15/1999	Johansson et al.		

Examiner  
Signature

/Isis Ghali/

Date  
Considered

02/02/2008

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box , Alexandria, VA 22313-1450.

MW1093003

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

4

**Complete if Known**

Application Number	10/802,342
Filing Date	March 17, 2004
First Named Inventor	Peter M. J. Bedding
Group Art Unit	1615
Examiner Name	
Attorney Docket Number	7593-CIP

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/I.G./		"B-Glucan", website at www.lsbu.ac.uk/water/hygly, pp. 1-2.	
		"Frequently Asked Questions About Beta Glucan 1, 3 D Glucan", About betaglukan.com website, pp. 1-4.	
		"Strengthening My Immune System With Beta Glucan", About betaglukan.com website, pp. 1-5.	
		"Gastric Ulcers in Horses: A Widespread but Manageable Disease", www.equinecentre.com.au/health_diseases_ulcers.shtml, pp. 1-4.	
		"Triple Crown Horse Feeds: Equimix Technology", www.triplecrownfeed.com/equimixtech.php, pp. 1-4.	
		"Ultra Mannan Oligosaccharide", www.ultrateck.net/petfood/yeasts.html, pp. 1-2.	
		"DevRx Laboratories, Inc. makes horses healthier with BioEquine™!" horses.about.com/cs/news/a/bioequine1592.html.	
		MILLER, ALAN L., ND, "Therapeutic Considerations of L-Glutamine: A Review of Literature", www.thorne.com/altmedrev/fulltext/glutamine4-4.html, December 2002, pp. 1-12.	
		"Power Plus™ L-Glutamine: Body Builders Love Our L-Glutamine" www.pricespw.com/lglutamine, pp. 1-6.	
		"A Bit About Our Products: Hyaluronic Acids", www.kemme.ca/prodmain.html, pp. 1-4.	
/I.G./		"DrHormone.com - Vitamins and Supplements", www.schwarzbeinprinciple.com/pgs/vitamins_01.html, pp. 1-5.	

Examiner  
Signature

/Isis Ghali/

Date  
Considered

02/02/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

4

**Complete If Known**

Application Number	10/802,342
Filing Date	March 17, 2004
First Named Inventor	Peter M. J. Bedding
Group Art Unit	1615
Examiner Name	
Attorney Docket Number	7593-CIP

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/I.G./		"Single Amino Acids", www.intensivenutrition.com/SingleAminoAcids.htm, pp. 1-5.	
		"Solgar Amino Acids", www.allabout-solgar-vitamins.com/solgar-amino-acids.html, pp. 1-4.	
		BRIGGS, KAREN, "Provided By: The Horse Interactive Malicious Mycotoxins", www.thehorse.com/print.asp?fid=3695, pp. 1-4.	
		"Frequently Asked Questions: How Common is EGUS?", gastrogard.us.merial.com/faq.asp, pp. 1-4.	
		"Sites of Drug Action", www.egus.org/vet/treatment4.htm, pp. 1-3.	
		"The Truth: About Beta Glucan Products", www.beta-glucan-13d.com, pp. 1-4.	
		LANIGAN, A.J., "Uptake Mechanism of Beta Glucan", www.Beta-glucan-13d.com/beta-glucan-mechanism.htm, pp. 102.	
		"Beta Glucan Research - Saccharomyces cerevisiae", ww.betaglucan.org, pp. 1-7.	
		"β-glucan", www.ceapro.com/_pages/Beta_glucan.htm, one page.	
		"Phospholipids", users.rcn.com/jkimball.ma.ultranet/BiologyPages/P/Phospholipids.html, one page.	
/I.G./		"oligosaccharide", encarta.msn.com/encnet/features/dictionary/DictionaryResults.aspx?refid=1861634848, one page.	

Examiner  
Signature

/Isis Ghali/

Date  
Considered

02/02/2008

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

4

**Complete if Known**

Application Number

10/802,342

Filing Date

March 17, 2004

First Named Inventor

Peter M. J. Bedding

Group Art Unit

1615

Examiner Name

Attorney Docket Number

7593-CIP

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/I.G./		"Re: ProfHeath--membrane synthesis", 216.239.33.100/search?q=cache:H3_DvEn0rMEC:www.cquest.utoronto.ca/botany/bio250y/talk/lectures/lec3/mesages.html, one page.	
		RUSSETT, Dr. J.C., "Specialty Products Research Notes: Lecithin and Equine Ulcers", Central Soya, LEC-H-55, March 2002, pp. 1-10.	
		"L-Threonine", www.ajinomoto.co.jp/ajinomoto/A-Life/e_aminoscience/bc/amino_16.html, one page.	
		ADAMS, Dr. CLIFFORD A., "What are Nutricines?", www.eclecticcooking.com/WhatAreNutricines.htm, pp. 1-2.	
		LARDY, GREG, POLAND, CHIP, "Feeding Management for Horse Owners", AS-953, www.ext.nodak.edu/extpubs/ansci/horse/as953w.htm, Feb. 2001, pp. 1-6.	
		"Mycosorb", translate.google.com/translate?hl=en&sl=pt&u=http://www.va-industria.pl/support.html&prev=/search%3Fq%3Dmycosorb%26hl%3Den%26, one page.	
		"Alltech to Exhibit Range of Natural Products at Space 2002", www.alltech-bio.com/alltech%5Calltech2.nsf/pages/News_Alltech_to_Exhibit_Range_of_Natural_Products_at_Space_2002, one page.	
		"Unraveling the Mystery of Mycotoxins", www.alltech-bio.com/alltech%5Calltech2.nsf/pages/News_UNRAVELLING_THE_MYSTERY_OF_MYCOTOXINS, one page.	
		"Consistent Responses Confirm Bio-Mos Efficacy", www.alltech-bio.com/alltech%5Calltech2.nsf/pages/News_CONSISTENT_RESPONSES_CONFIRM_BIO-MOS_EFFICACY, one page.	
		"L-Glutamine Side Effects and Benefits", www.bodybuildingforyou.com/supplements-reviews/glutamine-side-effects-benefits.htm, pp. 1-2.	
		MILLER, ALAN L. M.D., "Therapeutic Considerations of L-Glutamine: A Review of the Literature", pp. 1-11.	
/I.G./		REYNOLDS, JUDITH A., Ph.D. P.A.S., "Are You Feeding Your Horse Like a Horse?", Moorman's Feed Facts, October 2000, pp. 1-4.	

Examiner  
Signature

/Isis Ghali/

Date

Considered

02/02/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.